Hispanic patients show a lower risk and longer time to a second cutaneous squamous cell carcinoma than matched non-Hispanic ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...

Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT(TM) (cosibelimab-ipdl). UNLOXCYT is the first ...

US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT ™ (cosibelimab-ipdl). UNLOXCYT is the first and ...

GT Biopharma, Inc. (the "Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

The definition is tricky, but the effects of poor metabolic health are clear — and can wreak havoc on the body.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

The IDEXX Cancer Dx Panel has already transformed cancer screening for veterinarians. Today, more than 5,500 practices across ...